From People To Planet: The Endless Potential Of CRISPR Gene Editing
Executive Summary
Caszyme CEO and 2022 Rising Leader Monika Paule is on a mission to expand the CRISPR toolbox of available proteins to enhance diagnostic tools, therapeutics and even agricultural practices.
You may also be interested in...
Idorsia And J&J Hypertension Drug Edges Closer To An Uncertain Market
The partners released positive data from a Phase III study of their resistant hypertension drug candidate, aprocitentan, and have already started talks with regulators, but its commercial prospects remain uncertain.
Stada Poised To Launch As Calliditas Finally Wins EU Nod For Kinpeygo
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.
Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.